Small Cell Lung Cancer

PRIMARY OR ADJUVANT THERAPY FOR LIMITED STAGE SCLC

Four cycles of cytotoxic chemotherapy are recommended.

Planned cycle length should be every 21–28 days during concurrent RT.

During cytotoxic chemotherapy + RT, Cisplatin/Etoposide is recommended.

The use of myeloid growth factors is not recommended during concurrent cytotoxic chemotherapy plus RT

●   Cisplatin 75 mg/m, Day 1 and Etoposide 100 mg/m Days 1, 2, 3

•  Cisplatin 60 mg/m2 Day 1 and Etoposide 120 mg/m Days 1, 2, 3

•  Carboplatin area under the curve (AUC) 5–6 Day 1 and Etoposide 100 mg/m Days 1, 2, 3

•  Cisplatin 25 mg/m2 Days 1, 2, 3 and Etoposide 100 mg/m Days 1, 2, 3

PRIMARY THERAPY FOR EXTENSIVE STAGE SCLC

Four cycles of cytotoxic chemotherapy are recommended,

but some patients may receive up to 6 cycles based on response and tolerability after 4 cycles.

Carboplatin AUC 5–6 Day 1 and Etoposide 80–100 mg/m2 Days 1, 2, 3

Cisplatin 75–80 mg/m Day 1 and Etoposide 80–100 mg/m2 Days 1, 2, 3

Carboplatin AUC 5 Day 1 and Irinotecan 50 mg/m2 Days 1, 8, 15

Cisplatin 60 mg/m2 Day 1 and Irinotecan 60 mg/m2 Days 1, 8, 15

Cisplatin 30 mg/m2 Days 1, 8 and Irinotecan 65 mg/m2 Days 1, 8